Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losmapimod in COPD
NCT01218126Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2010
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of losmapimod in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoint: Six Minute Walk Distance at 24 weeks. Started Nov 2010; status: completed.
02
Drugs
losmapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01218126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218126.